Maximizing Outcomes in Treating Acute Migraine

NCT ID: NCT03896009

Last Updated: 2023-08-24

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1594 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-04

Study Completion Date

2019-12-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults. AXS-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. This study is designed to evaluate the efficacy and safety of AXS-07 compared to meloxicam, rizatriptan, and placebo for the treatment of a migraine attack.

This is a randomized, double-blind, 4-arm, parallel group, single-dose, placebo-controlled trial. Subjects who successfully complete screening and continue to meet all entry criteria will be randomly assigned to take one dose of either AXS-07, meloxicam, rizatriptan, or placebo upon the occurrence of a qualifying migraine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AXS-07

Taken once upon a qualifying migraine

Group Type EXPERIMENTAL

AXS-07 (MoSEIC meloxicam and rizatriptan)

Intervention Type DRUG

AXS-07 taken once upon onset of a qualifying migraine.

Meloxicam

Taken once upon a qualifying migraine

Group Type ACTIVE_COMPARATOR

Meloxicam

Intervention Type DRUG

Meloxicam taken once upon onset of a qualifying migraine.

Rizatriptan

Taken once upon a qualifying migraine

Group Type ACTIVE_COMPARATOR

Rizatriptan

Intervention Type DRUG

Rizatriptan taken once upon onset of a qualifying migraine.

Placebo

Taken once upon a qualifying migraine

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo taken once upon onset of a qualifying migraine.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AXS-07 (MoSEIC meloxicam and rizatriptan)

AXS-07 taken once upon onset of a qualifying migraine.

Intervention Type DRUG

Meloxicam

Meloxicam taken once upon onset of a qualifying migraine.

Intervention Type DRUG

Rizatriptan

Rizatriptan taken once upon onset of a qualifying migraine.

Intervention Type DRUG

Placebo

Placebo taken once upon onset of a qualifying migraine.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has an established diagnosis of migraine with or without aura.
* Has experienced an inadequate response to prior acute treatments.

Exclusion Criteria

* Has previously received any investigational drug or device or investigational therapy within 30 days before Screening.
* Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Axsome Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Site

Birmingham, Alabama, United States

Site Status

Clinical Research Site

Birmingham, Alabama, United States

Site Status

Clinical Research Site

Mobile, Alabama, United States

Site Status

Clinical Research Site

Phoenix, Arizona, United States

Site Status

Clinical Research Site

Tempe, Arizona, United States

Site Status

Clinical Research Site

Little Rock, Arkansas, United States

Site Status

Clinical Research Site

Canoga Park, California, United States

Site Status

Clinical Research Site

Colton, California, United States

Site Status

Clinical Research Site

Culver City, California, United States

Site Status

Clinical Research Site

Encino, California, United States

Site Status

Clinical Research Site

Los Alamitos, California, United States

Site Status

Clinical Research Site

Los Angeles, California, United States

Site Status

Clinical Research Site

Oceanside, California, United States

Site Status

Clinical Research Site

Pomona, California, United States

Site Status

Clinical Research Site

Redlands, California, United States

Site Status

Clinical Research Site

Riverside, California, United States

Site Status

Clinical Research Site

San Diego, California, United States

Site Status

Clinical Research Site

Santa Monica, California, United States

Site Status

Clinical Research Site

Spring Valley, California, United States

Site Status

Clinical Research Site

Walnut Creek, California, United States

Site Status

Clinical Research Site

Waterbury, Connecticut, United States

Site Status

Clinical Research Site

Clermont, Florida, United States

Site Status

Clinical Research Site

DeLand, Florida, United States

Site Status

Clinical Research Site

Fernandina Beach, Florida, United States

Site Status

Clinical Research Site

Hallandale, Florida, United States

Site Status

Clinical Research Site

Hialeah, Florida, United States

Site Status

Clinical Research Site

Hollywood, Florida, United States

Site Status

Clinical Research Site

Jacksonville, Florida, United States

Site Status

Clinical Research Site

Lake City, Florida, United States

Site Status

Clinical Research Site

Lake Worth, Florida, United States

Site Status

Clinical Research Site

Miami, Florida, United States

Site Status

Clinical Research Site

Ocoee, Florida, United States

Site Status

Clinical Research Site

Orange City, Florida, United States

Site Status

Clinical Research Site

Orlando, Florida, United States

Site Status

Clinical Research Site

Ormond Beach, Florida, United States

Site Status

Clinical Research Site

South Miami, Florida, United States

Site Status

Clinical Research Site

Sunrise, Florida, United States

Site Status

Clinical Research Site

Tampa, Florida, United States

Site Status

Clinical Research Site

Atlanta, Georgia, United States

Site Status

Clinical Research Site

Atlanta, Georgia, United States

Site Status

Clinical Research Site

Stockbridge, Georgia, United States

Site Status

Clinical Research Site

Meridian, Idaho, United States

Site Status

Clinical Research Site

Evanston, Illinois, United States

Site Status

Clinical Research Site

Lenexa, Kansas, United States

Site Status

Clinical Research Site

Lexington, Kentucky, United States

Site Status

Clinical Research Site

Louisville, Kentucky, United States

Site Status

Clinical Research Site

New Orleans, Louisiana, United States

Site Status

Clinical Research Site

Boston, Massachusetts, United States

Site Status

Clinical Research Site

North Dartmouth, Massachusetts, United States

Site Status

Clinical Research Site

Watertown, Massachusetts, United States

Site Status

Clinical Research Site

Ann Arbor, Michigan, United States

Site Status

Clinical Research Site

Minneapolis, Minnesota, United States

Site Status

Clinical Research Site

Kansas City, Missouri, United States

Site Status

Clinical Research Site

Springfield, Missouri, United States

Site Status

Clinical Research Site

Las Vegas, Nevada, United States

Site Status

Clinical Research Site

Berlin, New Jersey, United States

Site Status

Clinical Research Site

Toms River, New Jersey, United States

Site Status

Clinical Research Site

Albuquerque, New Mexico, United States

Site Status

Clinical Research Site

Endwell, New York, United States

Site Status

Clinical Research Site

Manlius, New York, United States

Site Status

Clinical Research Site

New York, New York, United States

Site Status

Clinical Research Site

Rochester, New York, United States

Site Status

Clinical Research Site

The Bronx, New York, United States

Site Status

Clinical Research Site

Williamsville, New York, United States

Site Status

Clinical Research Site

High Point, North Carolina, United States

Site Status

Clinical Research Site

Wilmington, North Carolina, United States

Site Status

Clinical Research Site

Cincinnati, Ohio, United States

Site Status

Clinical Research Site

Cleveland, Ohio, United States

Site Status

Clinical Research Site

Dublin, Ohio, United States

Site Status

Clinical Research Site

Oklahoma City, Oklahoma, United States

Site Status

Clinical Research Site

Portland, Oregon, United States

Site Status

Clinical Research Site

Salem, Oregon, United States

Site Status

Clinical Research Site

Philadelphia, Pennsylvania, United States

Site Status

Clinical Research Site

Charleston, South Carolina, United States

Site Status

Clinical Research Site

Mt. Pleasant, South Carolina, United States

Site Status

Clinical Research Site

Knoxville, Tennessee, United States

Site Status

Clinical Research Site

Memphis, Tennessee, United States

Site Status

Clinical Research Site

Nashville, Tennessee, United States

Site Status

Clinical Research Site

Austin, Texas, United States

Site Status

Clinical Research Site

San Antonio, Texas, United States

Site Status

Clinical Research Site

Salt Lake City, Utah, United States

Site Status

Clinical Research Site

Charlottesville, Virginia, United States

Site Status

Clinical Research Site

Norfolk, Virginia, United States

Site Status

Clinical Research Site

Bellevue, Washington, United States

Site Status

Clinical Research Site

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

http://www.axsome.com

Axsome Therapeutics Website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AXS-07-301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ADX10059 Migraine Prevention Study
NCT00820105 TERMINATED PHASE2